Drug Profile
Research programme: CD137 agonists - Bicycle Therapeutics
Alternative Names: BCY 3814Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Class Antineoplastics; Drug conjugates; Peptides
- Mechanism of Action CD137 antigen agonists; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 21 Apr 2018 Preclinical trials in Cancer in USA (Parenteral)
- 21 Apr 2018 Interim pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)